Is Regulatory Scrutiny and Novo Nordisk Partnership Loss Changing the Investment Case for Hims & Hers Health (HIMS)?
Hims & Hers Health is facing a securities class action lawsuit following the past termination of its partnership…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made…
Health Canada approves Ozempic® to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease
Ozempic® is the first-and-only medication indicated for both the once-weekly treatment of adult patients with type 2 diabetes…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
European shares flat as investors await Ukraine talks
(Reuters) -European shares were little changed in early trade on Monday, with investors on the watch for Ukraine…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…
Will you take Wegovy to lose weight?
Wegovy is now available in Singapore more than two years after it was approved by the Health Sciences…
Microsoft to build world’s most powerful quantum computer in Denmark
Quantum technology is becoming very important for both business and global power. In the last ten years, the…
GLP-1 drugs for addiction: Confidence grows in new treatment option
WERNERSVILLE, Pa. — To make sense of the reds and greens dancing across a computer monitor displaying a…
Pancreatitis, Ozempic and exaggerated headlines: A UK alert raises concerns about drug abuse | Health
Last week, many media outlets reported on a press release from the UK Medicines and Healthcare products Regulatory…